Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00218517 · ClinicalTrials.gov registry record · Phase 2
Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1
A Phase 2 study of Marijuana Abuse, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT00218517: Completed Phase 2 study of Marijuana Abuse, sponsored by National Institute on Drug Abuse (NIDA).
NCT00218517 is a Phase 2 study of Marijuana Abuse that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 19 participants, below the 94-participant average among 4 other Marijuana Abuse trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00218517, a Phase 2 study of Marijuana Abuse, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
During the past 15 years, the demand for treatment for marijuana-related problems in the United States has increased nearly twofold. Selegiline is a medication currently used to treat nicotine dependence. The purpose of this study is to evaluate whether selegiline may be useful in treating individuals with marijuana dependence.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Selegiline hydrochloride
Study Locations (1)
Connecticut
- MRU - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2005-03 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
What the finished NCT00218517 record still lists
NCT00218517 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 94-participant average among 4 other Marijuana Abuse trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Marijuana Abuse appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00218517 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT00218517 about?
NCT00218517 is a clinical study titled "Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1". During the past 15 years, the demand for treatment for marijuana-related problems in the United States has increased nearly twofold. Selegiline is a medication currently used to treat nicotine dependence. The purpose of this study is to evaluate whether selegiline may be useful in treating individua...
What is the current status of trial NCT00218517?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2005-03. Estimated completion is 2007-07.
What conditions does trial NCT00218517 study?
This clinical trial studies the following conditions: Marijuana Abuse.
What interventions are being tested in trial NCT00218517?
The interventions under investigation include: Placebo (DRUG), Selegiline hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00218517?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00218517 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Marijuana Abuse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia